CIK 0001348362
- Non-accelerated filer
- Smaller reporting company
Lexaria Bioscience Corp.
Sign in to watch- Ticker
- LEXX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Aug 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 202000871
- Phone
- +1 250-765-6424
- Business address
- 100 - 740 MCCURDY ROAD, KELOWNA, British Columbia, Canada, V1X 2P7
- Former names
- Lexaria Corp., LEXARIA CORP.
- 4 Open-market buy CEO bought 15,000 shares at an average $0.21 ($3,188)
- 4 Open-market buy CEO bought 16,600 shares at an average $0.21 ($3,416)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy CEO bought 44,000 shares at an average $0.21 ($9,068)
- 4 Open-market buy CEO bought 36,000 shares at an average $0.21 ($7,430)
- 4 Open-market buy CEO bought 29,000 shares at an average $0.19 ($5,563)
- 4 Open-market buy CEO bought 17,570 shares at an average $0.19 ($3,399)
- 4 Open-market buy CEO bought 25,000 shares at an average $0.21 ($5,336)
- 4 Open-market buy CEO bought 12,500 shares at an average $0.18 ($2,220)
- 4 Open-market buy CEO bought 19,000 shares at an average $0.18 ($3,459)
- 4 Open-market buy CEO bought 32,110 shares at an average $0.18 ($5,799)
- 4 Open-market buy CEO bought 16,900 shares at an average $0.19 ($3,159)
- 4 Open-market buy CEO bought 81,500 shares at an average $0.18 ($15,037)
- 4 Open-market buy CEO bought 10,000 shares at an average $0.18 ($1,845)
- 4 Open-market buy CEO bought 23,000 shares at an average $0.18 ($4,164)
- 4 Open-market buy CEO bought 99,800 shares at an average $0.18 ($17,920)
- 4 Open-market buy CEO bought 59,256 shares at an average $0.18 ($10,559)
- 4 Open-market buy CEO bought 46,400 shares at an average $0.17 ($8,005)
- 4 Open-market buy CEO bought 66,750 shares at an average $0.17 ($11,614)
- 4 Open-market buy CEO bought 188,404 shares at an average $0.17 ($32,247)
Page 10 of 21 · 420 filings